Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Siefker-Radtke, A. O.
Loriot, Y.
Siena, S.
Beato, C.
Climent Duran, M. A.
Varlamov, S.
Duran, I.
Tagawa, S. T.
Geoffrois, L.
Mellado, B.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
